Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, every patient with cancer who is going to be treated by immunotherapy will fill in a form. In this form, we try to determine if he presents rheumatologic complications of his immunotherapy. If the patient answers yes to one question on the form, the patient will be see in rheumatologic consultation to explore his clinical signs.
The number of patients referred in consultation thanks to this questionnaire will be compared to the number of patients who would have been spontaneously referred by the oncologist.
The aim of this questionnaire is to optimise the management of rheumatological effects secondary to immunotherapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient with cancer immunotherapy treatment | Experimental | All patients starting immunotherapy treatment will complete a questionnaire to identify rheumatological side effects, each time they come for treatment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fill in a form | Other | Patient will have to fill in a form at each perfusion of immunotherapy to tell if they presents rheumatologic clinical signs |
|
| Measure | Description | Time Frame |
|---|---|---|
| to determine whether a self-questionnaire completed by a patient treated with immunotherapy can identify more patients with rheumatological side effects related to this treatment, compared to the complaint reported by the patient to the oncologist | number of patients referred to a rheumatology consultation thanks to the answers to the questionnaire compared to the number of patients referred to a consultation (from questionnaire and oncologist) | ONE YEAR |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Francoise Debiais, MD PHD | Contact | 00335 49 44 44 65 | francoise.debiais@chu-poitiers.fr | |
| Alice Bel | Contact | alice.bel@chu-poitiers.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| C.H.U de Poitiers | Recruiting | Poitiers | 86000 | France |
NO IPD
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
| D001327 | Autoimmune Diseases |
| D001168 | Arthritis |
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| ID | Term |
|---|---|
| D007154 | Immune System Diseases |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D064419 | Chemically-Induced Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided